Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
NYLIM Jacob Ballas India Fund III is a private equity fund focused on providing growth capital to companies operating in India. The fund is a joint venture between New York Life Investment Management and Jacob Ballas Capital India, targeting established businesses across various sectors. It maintains a significant focus on the healthcare, pharmaceutical, and life sciences industries, seeking to support companies with strong management teams and scalable business models. Through its investments, the fund provides not only capital but also strategic guidance and corporate governance expertise. Notable healthcare-related investments from this fund include companies in the pharmaceutical manufacturing and health insurance sectors.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on NYLIM Jacob Ballas India Fund III.